Standardized SEC financial data for IMMUCELL CORP /DE/ — income statement, balance sheet, cash flow and 40+ ratios, available as a clean JSON API. CIK 0000811641 · NASDAQ · In Vitro & In Vivo Diagnostic Substances.
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $15.3M | $19.2M | $18.6M | $17.5M | $26.5M | $27.6M |
| Cost of revenue | $8.5M | $10.6M | $10.9M | $13.6M | $18.6M | $16.2M |
| Gross profit | $6.9M | $8.7M | $7.6M | $3.9M | $7.9M | $11.4M |
| R&D expense | $4.4M | $4.2M | $4.5M | $4.4M | $3.9M | $3.0M |
| SG&A expense | $2.2M | $2.5M | $3.2M | $3.1M | $3.5M | $3.6M |
| Operating income | -$1.4M | $257K | -$2.3M | -$5.7M | -$1.6M | $1.6M |
| EBITDA | — | — | — | — | $1.1M | $4.4M |
| Interest expense | $481K | $314K | $349K | $476K | $529K | $443K |
| Pretax income | -$1.0M | -$69K | -$2.5M | -$5.8M | -$2.1M | -$1.0M |
| Income tax | $10K | $9K | $8K | $5K | $10K | $12K |
| Net income | -$1.0M | -$78K | -$2.5M | -$5.8M | -$2.2M | -$1.0M |
| EPS (diluted) | $-0.14 | $-0.01 | $-0.32 | $-0.75 | $-0.26 | $-0.12 |
Standardized from IMMUCELL CORP /DE/'s SEC filings — per-share figures split-adjusted. Full history via the API.
# JSON
curl https://sec-financial-api-production.up.railway.app/v1/company/ICCC/financials \
-H "X-API-Key: YOUR_KEY"
# CSV export (income / balance / cash-flow)
curl "https://sec-financial-api-production.up.railway.app/v1/company/ICCC/income-statement?format=csv" \
-H "X-API-Key: YOUR_KEY"